The Nanomedicine and Molecular Imaging Laboratory (NAMIL) is a section of the Radiology Department of the University of Pennsylvania which focuses research on the development of novel and multifunctional nanoparticle contrast agents for medical imaging applications.
Currently, the lab’s main focus is the development of gold and bismuth nanoparticles as contrast agents for computed tomography (CT). These nanoparticles have been further modified to have a variety of additional functional properties, such as fluorescence, MRI contrast or therapeutic effects.
The lab’s others areas of interest include novel computed tomography-based imaging methods, such as dual energy CT, spectral CT and iterative image reconstruction. These technologies are being applied for structural imaging and molecular imaging of the levels of specific cell types and proteins in vivo. These approaches provide enhanced characterization of cardiovascular diseases and cancers, which should allow improved selection of therapies and monitoring of response to treatments.
We believe that our science is better with a diverse team. We embrace and encourage our lab members’ differences in age, color, disability, ethnicity, family or marital status, gender identity or expression, language, national origin, ability, political affiliation, race, religion, sexual orientation, socio-economic status, veteran status, and other characteristics that make our lab members who they are.